OctoPlus N.V.

OctoPlus N.V. (AMS:OCTO) As part of the Company's recently announced strategic focus on developing controlled release formulations for clients, OctoPlus N.V. ("OctoPlus" or "the Company") (Euronext: OCTO) announces today that it has signed a new drug delivery technology evaluation contract with a US-based biotech company.

OctoPlus N.V. (AMS:OCTO) OctoPlus N.V. ("OctoPlus" or "the Company") (Euronext: OCTO), the drug delivery company, announces today that its Annual General Meeting of Shareholders (the "Meeting") has appointed the new Executive Board and adopted a change in the composition of the Supervisory Board of Directors.

OctoPlus N.V. (AMS:OCTO) OctoPlus N.V. (Euronext: OCTO), the drug delivery company, announces today that its CEO will present at the Rodman and Renshaw 10th Annual Healthcare Conference in New York next week.

OctoPlus N.V. (AMS:OCTO) OctoPlus N.V. ("OctoPlus" or "the Company") (Euronext: OCTO), the drug delivery company, announces today its results for the six-month period ended 30 June 2008. The Company also announces the publication of its Annual Report 2007.

OctoPlus N.V. (AMS:OCTO) OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery company, announces today the publication date for its Annual Report 2007 and its results for the six-month period ended 30 June 2008, and the date for its Annual General Meeting of Shareholders (AGM).

OctoPlus N.V. (AMS:OCTO) This agreement will immediately transform OctoPlus into a cashflow positive company OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery company, announces today that it has signed an exclusive license and product acquisition agreement to license its share of the commercial rights to its lead product Locteron® to co-development partner Biolex Therapeutics. OctoPlus will remain a partner in the process development and manufacture of Locteron, but without having to make the investments for the upcoming late-stage clinical program. The proceeds of the agreement include among others upfront and milestone payments that amount to a total of US$ 149 million (€ 108 million) in the coming years, and royalties on future Locteron sales. The upfront fee and short-term milestone payments comprise the first significant revenues that OctoPlus generates from the commercialisation of its drug delivery technology PolyActive®. In addition to the cash pa ...

OctoPlus N.V. (AMS:OCTO) OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery and development company, announces today that the Board of Supervisory Directors will propose to expand the Executive Board with two new members at the next general meeting of shareholders later this year. The new Board will consist of Chief Executive Officer, Simon Sturge, Joost Holthuis, current CEO and founder, who will take up the new position of Chief Operating Officer, Chief Financial Officer Hans Pauli and Chief Business Officer Gerben Moolhuizen.

OctoPlus N.V. (AMS:OCTO) OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery and development company, announces today that it has received an additional € 0.75 million from its co-development partner Biolex Therapeutics as part of its recently announced bridge financing. The payment by Biolex will expand OctoPlus' bridge financing to a total of € 6.75 million. The other participants in the bridge financing are OctoPlus' major shareholders Life Sciences Partners and SR One.

OctoPlus N.V. Following the approval by the Extraordinary General Meeting of Shareholders on 30 May 2008 to delay publication of the 2007 Annual Report, OctoPlus N.V. (Euronext: OCTO) announces today that it will also postpone publication of its results for the first 6 months of 2008, previously scheduled for August 1, until after the 2007 Annual Report is published.

OctoPlus N.V. OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery and development company, announces today that efficacy of OP-145, a novel therapy for the treatment of chronic middle ear infection (otitis media), was demonstrated in an interim analysis of the Phase II study. As a result, OctoPlus will close the study because its goal has been achieved.